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Abstract
Backgrounds: Despite reported discordance between the mutational status of primary lung cancers and their
metastases, metastatic sites are rarely biopsied and targeted therapy is guided by genetic biomarkers detected in
the primary tumor. This situation is mostly explained by the apparent stability of EGFR-activating mutations. Given
the dramatic increase in the range of candidate drugs and high rates of drug resistance, rebiopsy or liquid biopsy
may become widespread. The purpose of this study was to test genetic biomarkers used in clinical practice (EGFR,
ALK) and candidate biomarkers identified by the French National Cancer Institute (KRAS, BRAF, PIK3CA, HER2) in
patients with metastatic non-small-cell lung cancer for whom two tumor samples were available.
Methods: A retrospective study identified 88 tumor samples collected synchronously or metachronously, from
the same or two different sites, in 44 patients. Mutation analysis used SNaPshot (EGFR, KRAS, BRAF missense
mutations), pyrosequencing (EGFR and PIK3CA missense mutations), sizing assays (EGFR and HER2 indels) and
IHC and/or FISH (ALK rearrangements).
Results: About half the patients (52 %) harbored at least one mutation. Five patients had an activating
mutation of EGFR in both the primary tumor and the metastasis. The T790M resistance mutation was
detected in metastases in 3 patients with acquired resistance to EGFR tyrosine kinase inhibitors. FISH showed
discordance in ALK status between a small biopsy sample and the surgical specimen. KRAS mutations were
observed in 36 % of samples, six patients (14 %) having discordant genotypes; all discordances concerned
sampling from different sites. Two patients (5 %) showed PI3KCA mutations. One metastasis harbored both
PI3KCA and KRAS mutations, while the synchronously sampled primary tumor was mutation free. No mutations
were detected in BRAF and HER2.
Conclusions: This study highlighted noteworthy intra-individual discordance in KRAS mutational status, whereas EGFR
status was stable. Intratumoral heterogeneity for ALK rearrangement suggests a limitation of single-biopsy analysis for
therapeutic strategy with crizotinib.
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Background
Chemotherapy is still the standard treatment for meta-
static non-small-cell lung cancer (NSCLC), which repre-
sents 60 % of cases at diagnosis. Overall and progression-
free survival rates have gradually improved, notably with
the use of different drugs or combinations and more pre-
cise histological classification [1,2]. However, median sur-
vival in advanced disease is still less than 12 months, even
among patients receiving platinum-based doublet chemo-
therapy and bevacizumab [1,3]. The recent introduction of
tyrosine kinase receptor inhibitors for the EGFR and ALK
genes [4–8], which are mutated in respectively 10 and 4 %
of non-small-cell lung tumors in Caucasian patients, has
had a major impact, despite occasional resistance muta-
tions such as T790M in the EGFR gene, which is found in
more than 50 % of patients treated by tyrosine kinase in-
hibitor (TKI) [9,10]. Several clinical trials are underway,
based on genetic biomarkers and activation pathway in-
hibitors. The intracellular oncogene KRAS is a particularly
attractive target because of its high mutation rate (>25 %
of patients), especially in current and former heavy
smokers [11].
A major issue raised by targeted therapies is potential
discordance between the mutational status of the pri-
mary tumor and its metastases, or between two regions
of the same tumor. This is particularly important in lung
cancer: repeat biopsy is rarely performed [12], even
though various studies have shown discrepancies in
EGFR, ALK and KRAS mutational status [13–18].
The present study examined discordance between repeat
samples from the same tumor site or samples from two
different sites, collected synchronously or metachronously.
The principal mutations of EGFR, ALK, KRAS, BRAF,
PIK3CA and HER2 were analyzed in 44 patients with non-
small-cell lung cancer. The KRAS, BRAF, PIK3CA and
HER2 oncogenes were selected because they represented
potential drug targets [19]. They were identified as poten-
tially predictive biomarkers in NSCLC by the French
National Cancer Institute (INCa) and were introduced in
the French nationwide initiative for tumor molecular pro-
filing during the 2010–2014 period [20].
Methods
Patients
This retrospective cohort study included patients with
non-small-cell lung cancer (adenocarcinoma or squa-
mous cell carcinoma) for whom two tumor samples
were available, collected synchronously or metachro-
nously either from the same site or from two different
sites during disease course between 2005 and 2012. Pa-
tients were identified by cross-matching information
from surgical files (surgical biopsy of metastasis, analysis
of lobectomy or pneumonectomy specimen, or bronchial
biopsy) with the medical codes of the institution. The
corresponding tissue blocks were identified in each case.
Samples were obtained by simple biopsy (n = 47; 53.4 %),
surgical excision or biopsy (n = 39; 44.3 %), or fine-
needle aspiration cytology (n = 2; 2.3 %).
Ethics statement
The study was conducted in accordance to the Declar-
ation of Helsinki principles. It was approved by the Hu-
man Research Ethics Committee of Brest University
Hospital (“Comité de Protection des Personnes - Ouest
VI”; January 18, 2012). Written informed consent for the
use of tissues and clinical data for research was taken
from patients at the time of procurement of tumor
specimens.
DNA extraction
All tumor samples were formalin-fixed and embedded in
paraffin (FFPE). In each case, the percentage of tumor
cells was determined by an experienced pathologist on a
representative histological cross-section. Samples from
at least three serial 10-μm sections were macrodissected
and pooled for DNA extraction. DNA was extracted
using the Maxwell® 16 FFPE Plus LEV DNA purification
kit (Promega, Madison, WI, USA) according to the man-
ufacturer’s instructions.
Mutational analyses
EGFR, KRAS, BRAF and PI3KCA status
Fragment-length analysis was used to screen for deletions
and insertions in EGFR exons 19 and 20 and in HER2 exon
20. Genomic tumor DNA was amplified using the Qiagen™
Multiplex PCR kit (Qiagen, Hilden, Germany) with the fol-
lowing primers: 5′-N-CTG-GAT-CCC-AGA-AGG-TGA-
GA-3′ and 5′-GAT-TTC-CTT-GTT-GGC-TTT-CG-3′ (E
GFR exon 19), 5′-N-CTC-CAG-GAA-GCC-T AC-GTG-
AT-3′and 5′-CTG-CGT-GAT-GAG-CTG-CAC-3′ (EGFR
exon 20), and 5′-N-CCT-CTC-AGC-GTA-CCC-TTG-TC-
3′ and 5′-AGG-GCA-TAA-GCT-GTG-TCA-CC-3′ (HER2
exon 20). For universal labeling, the forward primers were
tailed with a short nucleotide sequence (N) that matched a
universal FAM-labeled probe [21]. The labeled PCR prod-
ucts were subjected to capillary electrophoresis on an ABI
PRISM 3100 XL genetic analyzer (Applied Biosystems,
Courtabœuf, France) and compared with the wild-type
PCR product to determine whether differences in length
were present and represented deletion or insertion. Positive
samples were re-amplified and sequenced using the BigDye
Terminator v.1 cycle sequencing kit (Applied Biosystems),
according to the manufacturer’s protocol. Sequence electro-
phoregrams were interpreted using SeqPatient analysis soft-
ware version 3.5.2 (JSI Medical Systems, Ettenheim,
Germany).
The EGFR, KRAS and BRAF genes were analyzed for
presence of missense mutations using the ABI PRISM
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SNaPshot Multiplex kit (Applied Biosystems). Briefly,
three multiplex PCRs were designed, the first for KRAS
exon 2 (codons 12 and 13) and BRAF exon 15 (codon
600), the second for KRAS exon 3 (codon 61) and 4
(codon 146) and the third for EGFR exons 18 (codon 719)
and 20 (codon 790). Multiplex PCR used the Qiagen™
Multiplex PCR kit with a total volume of 20 μL. PCR
products were treated with Exonuclease I (ExoI) and
shrimp alkaline phosphatase (SAP) (USB, Cleveland, Ohio,
USA). Each extension primer (SNaPshot primer) was de-
signed to anneal to the reverse strand of its targeted PCR
product adjacent to the mutation site of interest. SNaP-
shot primers contained an additional tail at their 5’ end
for simultaneous detection. Mutation detection reactions
were performed in a total volume of 5 μL, comprising
1.5 μL SAP/ExoI-treated PCR product, 2 μL SNaPshot
Multiplex Ready Reaction mix and 1.5 μL SNaPshot pri-
mer mix (each primer at a final concentration of 0.5 to
1.5 μM). Products were treated with SAP before auto-
mated sequencing (ABI PRISM 3500 Dx Genetic Analyzer,
Applied Biosystems). Data were analyzed with GeneMap-
per Analysis software version 4.0 (Applied Biosystems).
The EGFR L848R mutation and PIK3CA exons 10 and
21 (codons 542, 545, 546, 1043, 1044, 1047 and 1049)
were analyzed by pyrosequencing. For each target, PCR
amplification was performed using the Qiagen™ Multi-
plex PCR kit with one of the primers biotinylated. Bio-
tinylated products were immobilized on streptavidin-
coated beads. After washing steps, DNA samples were
released by denaturation in NaOH and annealed into
single strands to a sequencing primer. Pyrosequencing
was performed on a PyroMark Q24 system (Qiagen) fol-
lowing the manufacturer’s instructions. PCR primers, se-
quencing primers and dispensing orders are available
upon request.
ALK status
ALK rearrangement was investigated in FFPE samples
(3 μm thick) by Fluorescent In Situ Hybridization (FISH)
and/or ImmunoHistoChemistry (IHC). FISH was per-
formed on Superfrost ® Plus slides (Thermo Scientific,
Saint-Herblain, France) with the Vysis LSI ALK Dual
Color break-apart rearrangement probe (Abbott Molecu-
lar, Abbott Park, IL, USA). The slides were read using a
Carl Zeiss epifluorescence microscope and the ISIS digital
image analysis system (Isis in situ imaging system v.5.3,
Metasystems, Altlussheim, Germany). FISH-positive cases
were defined as those presenting >15 % split signals or an
isolated orange signal in tumor cells. At least 100 nuclei
were assessed for each tumor sample. Immunostaining
with ALK monoclonal antibody (1:25, clone 5A4, Clinis-
ciences, Nanterre, France) was performed using the Ven-
tana Benchmark XT® automated slide preparation system
and the OptiView DAB IHC Detection Kit according to
the manufacturer’s instructions (Roche Diagnostics,
Mannheim, Germany). ALK IHC scores, based on staining
intensity and the percentage of tumor cells with positive
cytoplasmic staining, were assigned as follows: 0, no
stained cells; 1, faint or weak staining in >5 % cells or any
staining intensity in ≤5 % of tumor cells; 2, moderate
staining intensity in >5 % of tumor cells; or 3, strong
granular staining intensity in >5 % of tumor cells.
Availability of data and materials
A dataset (mutations detection) supporting the conclusions
of this article is available in Additional file 1: Figure S1.
Statistical analyses
Fisher’s exact test was used to identify significant factors
for discordance in mutational status between two sam-
ples from a given patient.
Results
Study population
Table 1 summarizes demographic characteristics. There
were 44 patients (27 male, 17 female) for whom two
samples could be analyzed by molecular biology (pri-
mary tumor and metastasis or two samples from the
same site). Current or former heavy smoking (>10 pack
years) was reported in the majority of cases (32/44).
Mean age at diagnosis was 60.5 years, slightly below the
French national average [22]. More than half the patients
had stage IV disease at diagnosis. All patients had non-
small-cell lung cancer; the predominant histological type
Table 1 Patient characteristics
Number Total (%)




Never smokers 7 16










Average time between samples (months)
Synchronous 1.2 (n = 13)
métachronous 18 (n = 31)
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was adenocarcinoma (41/44). Synchronous samples were
defined as being obtained within a 3-month period dur-
ing which no cancer treatment was administered.
The population was divided into patients sampled
twice at the same pulmonary site (18 patients: 12 syn-
chronous and six metachronous samples), and patients
sampled at two different sites: lung and another organ,
two different pulmonary sites, or two organs other than
the lung (26 patients: six synchronous and 20 metachro-
nous samples) (Fig. 1). Remote metastases were situated
in the brain (n = 8), lung (n = 5), pleura (n = 4), bone (n = 3),
lymph node (n = 4), liver (n = 3) or skin (n = 2).
Discordance in mutational status
About half the patients (52 %) harbored at least one mu-
tation. The distribution of the mutations detected in the
44 patients and 88 samples is shown in Fig. 1.
EGFR, KRAS, BRAF and PI3KCA mutations
Five patients had an activating mutation of EGFR (L858R,
or exon 19 deletion) in both the primary tumor and the
metastasis. No discordances were found in these cases.
None of these patients had additional mutations in KRAS,
BRAF or PI3KCA. One discordance was not taken into ac-
count for analysis, as the patient, a non-smoking female,
appeared to have two synchronous tumors; both these pri-
mary tumors were tested for EGFR activating mutations.
As shown in Fig. 2, the tumor in the right upper lobe har-
bored an apparent 12 bp deletion corresponding to the
p.Glu746_Thr751delinsValAla mutation (COSMIC muta-
tion ID: COSM53205), while the tumor in the left upper
lobe harbored a 15 bp deletion resulting in the p.Glu746_A-
la750del mutation (COSM6225). These two distinct EGFR
mutations were confirmed on repeat biopsy several months
later. It is noteworthy that both tumors progressed syn-
chronously under TKI treatment, and were subsequently
found to be p.Thr790Met (T790M)-positive (COSM6240).
In all, the p.Thr790Met (T790M) resistance mutation
was found in metastases in three patients, but this was
not considered as discordance because the initial activat-
ing mutation was still present in the metastasis.
Six cases of discordance in KRAS status were found: 3 be-
tween synchronous samples and 3 between metachronous
samples. Three of the discordances involved KRAS muta-
tion in the metastasis, while mutations were detected only
in the primary tumor in another patient. The remaining
two patients harbored different mutations in the primary
tumor and in the metastasis. Interestingly, the G12C muta-
tion (COSM516) was detected in eight of the 12 patients
with KRAS mutation in the primary tumor and/or metasta-
sis. All these patients were current heavy smokers.
Two patients showed PI3KCA mutations: p.His1047Arg
(H1047R; COSM775) and p.Glu542Lys (E542K; COS
M760). It is noteworthy that PI3KCA E542K mutation
was concomitant with KRAS G12C mutation in the me-
tastasis of a man in whom the synchronously sampled pri-
mary tumor was mutation-free.
ALK gene rearrangements
ALK status was introduced in routine practice in 2011
after it was recognized as a molecular target of crizotinib
in non-small-cell lung cancer [23]. Due to lack of mater-
ial, we were not able to retrospectively study all the sam-
ples obtained between 2005 and 2011 included in the
study. In total, ALK status was evaluated in 25 patients
using immunochemistry (n = 19), fluorescence in situ
hybridization (n = 7) or both (n = 2). Discordance was
observed in two former smokers. A female showed ALK
rearrangement in the primary tumor (17 % break-apart
signals) on FISH, but was negative in the metastatic
brain tumor (FISH: 1 %); interestingly, KRAS testing led
to the opposite result: detection of the G12C mutation
in the metastatic but not in the primary lesion. The sec-
ond case was a male, positive for ALK FISH in a small
biopsy specimen (FISH: 25 %), whereas the ALK
Table 2 Distribution of mutations in patients with samples from different sites. Ln: lymph node; WT: wild type, patients with
discordant status one patient with two distinct synchronous lung cancers
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alteration was not detected in the resection specimen
(FISH: 2 %): i.e., discrepancy between biopsy sample and
surgical specimen of a regionally localized stage II lung
cancer (Fig. 3).
Discordance analysis
The seven cases of discordance (eight mutational discor-
dances in a total seven patients, one patient showing dis-
cordances in both ALK and KRAS mutation status) were
analyzed with respect to gender, smoking status, cancer
treatment, time between the two samples from a given
patient, and type of second sample (repeat primary bi-
opsy versus biopsy of metastasis). Six discordances were
found in the 26 patients sampled at two distinct sites
Table 2; however, the study lacked power to demonstrate
any significant difference in risk compared to the 18 pa-
tients sampled twice at the same site (6/26 versus 1/18
cases of discordance; p = 0.24, Fisher’s exact test). The
metastases involved in these cases of discordance were
located in the lung (1/6), brain (3/6), bone (1/6) or
pleura (1/6). There were no other trends.
Discussion
Despite many recent studies of discordance in mutation
status between primary lung tumors and their metasta-
ses and the feasibility of tumor rebiopsy [12], metastatic
sites are rarely biopsied, as the results would currently
have few if any direct therapeutic implications. Discord-
ant responses to chemotherapy or tyrosine kinase inhibi-
tors have also been described between primary tumors
and their metastases, suggesting the existence of bio-
logical differences [24]. However, targeted therapies are
usually administered on the basis of the mutational
Fig. 1 Distribution of multigene mutations and discordances (EGFR, KRAS, BRAF, HER2 and PIK3CA) in 44 French patients with metastatic non-
small-cell lung cancer. The study population was composed of 26 patients sampled at different sites and 18 patients sampled twice at the same
primary lung cancer location. Synchronous or metachronous status was taken into account in each group
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Fig. 2 Screening for EGFR exon 19 deletions and the T790M resistance mutation in two independent tumors (right versus left upper lung lobe)
diagnosed synchronously. a Fragment-length analysis and Sanger sequencing demonstrating two different EGFR deletions in the two independ-
ent tumors. b SNaPshot analysis showing simultaneous emergence of the T790M resistance mutation in the two tumors after completion of EGFR
TKI therapy
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status of the primary tumor, which is most amenable to
biopsy (bronchoscopy).
Major KRAS mutations were frequent in the present co-
hort (36.4 %), as generally reported in northern and west-
ern France [25]. EGFR activating mutations were also
frequent (13.6 %): this may be explained by the fact that
patients with EGFR activating mutations are more likely
to be rebiopsied, as they progress under TKI therapy.
There was only one discordance in EGFR mutation, in a
patient with different activating mutations at two distinct
pulmonary sites considered as two synchronous primary
tumors (Fig. 2). Other activating mutations were present at
both sites. The p.Thr790Met (T790M) resistance mutation
was found in metastases in three patients, but this was not
considered as discordance because the initial activating
mutation was still present in the metastasis. Our findings
are slightly at odds with those of several other series which
reported discordances in EGFR status [26–28]. Recent
series also showed a very low rate of discordance in EGFR
status, consistent with the present results [29]. The lack of
discordance with respect to EGFR activating mutations is
consistent with their “driver” status.
The present rate of discordance in KRAS mutational
status (13.6 %) is consistent with that observed in several
other studies [14,15,24]. We found three types of dis-
cordance: i) mutation at the primary but not the meta-
static site, ii) mutation at the metastatic site, and iii) one
mutation at the primary site and a different mutation in
the metastasis. This variability of KRAS mutational sta-
tus may reflect the fact that it behaves as a “passenger”
mutation that, by definition, barely influences tumor
outcome. We found a high rate of mutations in codons
12 and 13 of the KRAS gene (37.2 %), particularly the
p.Gly12Cys (G12C) mutation. This mutation is usually
Fig. 3 ALK rearrangement status and ALK expression determined by fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC) in
two regions of the same primary lung tumor. a, b examination after hematoxylin-eosin-safran (HES) staining (×400): histological features of adeno-
carcinoma from the bronchoscopy (a) and the surgical resection (b) specimens. c, d ALK expression: very faint positive immunoreactivity (score,
0/1) in both the small biopsy and the corresponding surgical resection specimen. e, f Typical break-apart pattern observed by FISH (arrow): 25 %
of rearranged tumor nuclei detected in the biopsy sample, versus 2 % in the excision specimen
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associated with tobacco smoking [30–32]. Consistently,
in the present study, at least 32 of the 44 patients had
history of heavy smoking.
In one patient, the sampled metastasis harbored two dif-
ferent mutations: KRAS p.Gly12Cys (G12C) and PI3KCA
p.Glu542Lys (E542K). This is in agreement with recent
studies [29], confirming the possible coexistence of muta-
tions, a concept that was long contested.
None of the study parameters (gender, smoking, age, anti-
cancer treatment between samples) was significantly associ-
ated with overall risk of discordance. Although the
difference could not be shown to be statistically significant,
it is noteworthy that all six discordances involved patients
sampled at two different sites, synchronously or metachro-
nously, while only one involved patients sampled twice at
the same site.
The discordances observed in patients sampled at two
different sites might result from divergent evolution over
time, with a possible influence of microenvironment
and/or treatment effects. The advent of NGS (next gen-
eration sequencing) will probably extend such studies to
larger populations, with dependence on the quality of
the tumor tissue sampled. These new techniques are also
expected to determine the molecular profile of each
tumor site and to determine affiliation between two
tumor sites with certainty.
Discordances between ALK status in primary lesions
and their corresponding metastases and in multiple pri-
mary lesions have been reported in a subset of patients
with NSCLC [16,17]. The present study found different
types and levels of discordance in two patients unre-
sponsive to crizotinib.
The first patient was a female who had at least a 30
pack-year history of smoking. She underwent surgical re-
section of brain metastasis (ALK negative) and, there-
after, received crizotinib for 6 months. The best
response to ALK TKI administration was stable disease.
ALK TKI was switched to radio-chemotherapy, which
was well tolerated and led to reduction of the primary
lung cancer. Although FISH is widely used as a gold
standard method to diagnose ALK-rearranged NSCLC, it
is important to remember that testing by FISH does not
have 100 % sensitivity and specificity and shows cellular
false-negatives and false-positives [33,34]. Here, the pa-
tient’s primary tumor tissue sample was borderline posi-
tive on FISH; the percentage of ALK rearrangements fell
in the 15 to 20 % range. Giving the clinical history of the
patient, it may be assumed that FISH led to a false-
positive result.
The second patient was a male lifelong heavy smoker
(35 packs-years) who developed lung cancer at 68 years of
age. He was diagnosed after bronchial biopsy of a
pT2N0M0 non-small-cell lung carcinoma. He underwent
surgical resection of the lung cancer with standard
lymphadenectomy. The disease relapsed 10 months after
surgery, with lymph nodes and cerebral metastasis. At the
first attempt, the patient received cisplatin-pemetrexed
chemotherapy. CT scan showed remarkable lung tumor
shrinkage (>50 %) and a stable cerebral lesion. After a few
weeks, however, the patient asked to stop maintenance
therapy, and the disease progressed rapidly. At this stage,
the patient was treated with crizotinib. Despite dose re-
ductions, the patient experienced severe renal failure that
forced us to prematurely stop the targeted therapy. After
2 months of daily ALK TKI administration, the tumor
manifested no response. This case is different in that the
patient displayed discordance in ALK status between two
regions of the same tumor: a small biopsy specimen
showed an ALK rearrangement that was not detected in
the surgical specimen of the corresponding regionally lo-
calized lung cancer. This illustrates the clonal evolution of
lung tumors and the fact that ALK-positive clones sam-
pled by biopsy may not necessarily be representative of
the entire tumor. A situation exactly opposite was very re-
cently reported by Abe and collaborators [18]. While our
manuscript was under review, a paper appeared showing
an intratumor heterogeneity of ALK rearrangement in a
total of 7 NSCLC tumor samples (seven out of ten ALK
positive tumors detected in a series of 105 mixed adeno-
carcinomas and 17 adenosquamous carcinomas). The au-
thors attributed the observed differences in ALK status to
the existence of different cell populations within the
tumor. In contrast to the apparent stability of EGFR-
activating mutations, they have evidenced a relationship
between ALK status and certain histologic subtypes. As
stated by the authors, this could suggest that rearrange-
ment of the ALK gene is a late event of tumorigenesis
[35]. Together, these observations suggest a limitation of
single biopsy-based analyses for predictive biomarker
tracking and personalized medicine.
Conclusions
In conclusion, this study confirms the substantial rate of
discordance in mutational status between primary tu-
mors and their metastases in patients with non-small-
cell lung cancer. Discordance mainly concerned KRAS,
an oncogene frequently mutated in lung cancer, particu-
larly in smokers. KRAS-positive lung cancer patients are
among the most refractory to available treatments, but
efforts to develop new therapies for these patients, in-
cluding anti-MEK drugs, are particularly intensive. The
present findings indicate that, with the development of
successful targeted therapies, KRAS-positive patients
would benefit from genetic testing of different samples.
Currently, and by contrast, the stability of EGFR status
between primary sites and metastases confirms that
there is no reason to systematically rebiopsy all patients,
as the results would have no direct therapeutic
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implications other than in clinical trials. The discordance
in ALK rearrangement found between a small biopsy
and the corresponding surgical specimen shows that it is
important to accumulate information about the bio-
logical behavior of infrequent genetic alterations with
predictive value. Intra-tumor heterogeneity is another
major source of concern in therapeutic resistance.
Additional file
Additional file 1: SNaPshot Multiplex analysis of KRAS codons 12 and
13 (HUGO Gene Nomenclature Committee #6407). (ODP 128 kb)
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